top of page


Fresenius and WuXi Biologics agree development partnership covering up to 37 biosimilar candidates
Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio.

nuaxia
Nov 32 min read


Transcenta and WuXi Biologics sign HiCB technology licensing and strategic collaboration
Transcenta Therapeutics and WuXi Biologics have entered a strategic licensing collaboration covering Transcenta's HiCB continuous bioprocessing technologies and ExcelPro media platform.

nuaxia
Sep 101 min read
bottom of page